Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Ratings for Stryker (NYSE:SYK) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 5 | 7 | 2 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 1 | 0 | 1 | 0 | 0 |
3M Ago | 4 | 6 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Stryker, revealing an average target of $378.57, a high estimate of $405.00, and a low estimate of $351.00. This current average has increased by 5.25% from the previous average price target of $359.67.
In examining recent analyst actions, we gain insights into how financial experts perceive Stryker. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Vijay Kumar | Evercore ISI Group | Lowers | Outperform | $365.00 | $370.00 |
David Roman | Goldman Sachs | Announces | Neutral | $372.00 | - |
Mike Matson | Needham | Announces | Buy | $392.00 | - |
Matt Miksic | Barclays | Raises | Overweight | $376.00 | $372.00 |
Larry Biegelsen | Wells Fargo | Raises | Overweight | $381.00 | $364.00 |
Jason Wittes | Roth MKM | Raises | Buy | $405.00 | $348.00 |
Danielle Antalffy | UBS | Raises | Neutral | $351.00 | $339.00 |
Matt O'Brien | Piper Sandler | Raises | Overweight | $380.00 | $375.00 |
Rick Wise | Stifel | Raises | Buy | $375.00 | $350.00 |
Ryan Zimmerman | BTIG | Raises | Buy | $369.00 | $366.00 |
Jeff Johnson | Baird | Raises | Outperform | $378.00 | $367.00 |
Shagun Singh | RBC Capital | Raises | Outperform | $386.00 | $360.00 |
Joshua Jennings | TD Cowen | Raises | Buy | $400.00 | $365.00 |
Vijay Kumar | Evercore ISI Group | Raises | Outperform | $370.00 | $340.00 |
To gain a panoramic view of Stryker's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Stryker analyst ratings.
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Stryker displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 9.73%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Stryker's net margin excels beyond industry benchmarks, reaching 15.03%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Stryker's ROE stands out, surpassing industry averages. With an impressive ROE of 4.17%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Stryker's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.99%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.67.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: SYK